Latest From Replicor Inc.
The latest developments in one of the US FDA's favorite pathways.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Replicor Inc.
- Senior Management
Jean-Marc Juteau, PhD, CEO
Marcia T Ruiz, PhD, Dir., Pharmaceutical Dev.
Luc Paquet, VP, R&D
- Contact Info
Phone: (450) 688-6068
500, Cartier Blvd. West, Ste. 135
Laval, H7V 5B7
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.